annual CFO:
$6.94B+$1.98B(+39.81%)Summary
- As of today (May 29, 2025), TAK annual cash flow from operations is $6.94 billion, with the most recent change of +$1.98 billion (+39.81%) on March 1, 2025.
- During the last 3 years, TAK annual CFO has fallen by -$3.06 billion (-30.62%).
- TAK annual CFO is now -30.62% below its all-time high of $10.00 billion, reached on March 31, 2022.
Performance
TAK Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
$1.47B-$970.23M(-39.82%)Summary
- As of today (May 29, 2025), TAK quarterly cash flow from operations is $1.47 billion, with the most recent change of -$970.23 million (-39.82%) on March 1, 2025.
- Over the past year, TAK quarterly CFO has dropped by -$533.27 million (-26.67%).
- TAK quarterly CFO is now -60.33% below its all-time high of $3.70 billion, reached on March 31, 2021.
Performance
TAK quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
$6.94B-$533.27M(-7.14%)Summary
- As of today (May 29, 2025), TAK TTM cash flow from operations is $6.94 billion, with the most recent change of -$533.27 million (-7.14%) on March 1, 2025.
- Over the past year, TAK TTM CFO has increased by +$1.98 billion (+39.81%).
- TAK TTM CFO is now -32.43% below its all-time high of $10.27 billion, reached on December 31, 2021.
Performance
TAK TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
TAK Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +39.8% | -26.7% | +39.8% |
| 3 y3 years | -30.6% | -57.2% | -30.6% |
| 5 y5 years | +12.6% | -14.2% | +12.6% |
TAK Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -30.6% | +39.8% | -57.2% | +125.5% | -30.6% | +39.8% |
| 5 y | 5-year | -30.6% | +39.8% | -60.3% | +125.5% | -32.4% | +39.8% |
| alltime | all time | -30.6% | +3167.3% | -60.3% | +223.0% | -32.4% | +867.0% |
TAK Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | $6.94B(+39.8%) | $1.47B(-39.8%) | $6.94B(-7.1%) |
| Dec 2024 | - | $2.44B(+25.2%) | $7.47B(+24.9%) |
| Sep 2024 | - | $1.95B(+78.1%) | $5.99B(+11.2%) |
| Jun 2024 | - | $1.09B(-45.4%) | $5.38B(+8.4%) |
| Mar 2024 | $4.96B(-31.4%) | $2.00B(+110.9%) | $4.96B(-7.3%) |
| Dec 2023 | - | $948.05M(-29.4%) | $5.35B(-24.0%) |
| Sep 2023 | - | $1.34B(+99.5%) | $7.04B(-3.0%) |
| Jun 2023 | - | $673.38M(-71.8%) | $7.26B(+0.3%) |
| Mar 2023 | $7.24B(-27.7%) | $2.39B(-9.5%) | $7.24B(-12.6%) |
| Dec 2022 | - | $2.64B(+69.2%) | $8.28B(-3.5%) |
| Sep 2022 | - | $1.56B(+139.9%) | $8.58B(-6.0%) |
| Jun 2022 | - | $650.14M(-81.0%) | $9.13B(-8.7%) |
| Mar 2022 | $10.00B(+4.9%) | $3.43B(+16.5%) | $10.00B(-2.6%) |
| Dec 2021 | - | $2.94B(+39.4%) | $10.27B(+8.4%) |
| Sep 2021 | - | $2.11B(+38.4%) | $9.48B(-2.4%) |
| Jun 2021 | - | $1.52B(-58.8%) | $9.71B(+1.8%) |
| Mar 2021 | $9.54B(+54.8%) | $3.70B(+72.2%) | $9.54B(+26.3%) |
| Dec 2020 | - | $2.15B(-8.2%) | $7.55B(+13.1%) |
| Sep 2020 | - | $2.34B(+72.5%) | $6.68B(+4.0%) |
| Jun 2020 | - | $1.36B(-20.7%) | $6.42B(+4.2%) |
| Mar 2020 | $6.16B(+108.0%) | $1.71B(+34.1%) | $6.16B(+11.1%) |
| Dec 2019 | - | $1.27B(-38.8%) | $5.55B(+9.0%) |
| Sep 2019 | - | $2.08B(+89.4%) | $5.09B(+37.8%) |
| Jun 2019 | - | $1.10B(+0.7%) | $3.69B(+24.6%) |
| Mar 2019 | $2.96B(-13.1%) | $1.09B(+34.0%) | $2.96B(-2.8%) |
| Dec 2018 | - | $814.36M(+18.7%) | $3.05B(+3.0%) |
| Sep 2018 | - | $686.11M(+84.9%) | $2.96B(-4.8%) |
| Jun 2018 | - | $371.06M(-68.5%) | $3.11B(-8.8%) |
| Mar 2018 | $3.41B(+41.1%) | $1.18B(+62.2%) | $3.41B(+0.5%) |
| Dec 2017 | - | $726.34M(-13.0%) | $3.39B(+19.9%) |
| Sep 2017 | - | $834.79M(+24.4%) | $2.83B(+8.1%) |
| Jun 2017 | - | $671.11M(-42.3%) | $2.62B(+8.3%) |
| Mar 2017 | $2.42B | $1.16B(+615.4%) | $2.42B(+3751.0%) |
| Dec 2016 | - | $162.48M(-73.9%) | $62.76M(-88.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2016 | - | $621.96M(+32.3%) | $527.15M(-0.3%) |
| Jun 2016 | - | $470.08M(-139.4%) | $528.82M(+148.9%) |
| Mar 2016 | $212.43M(-87.3%) | -$1.19B(-290.1%) | $212.43M(-88.0%) |
| Dec 2015 | - | $626.87M(+0.5%) | $1.77B(+8.2%) |
| Sep 2015 | - | $623.64M(+305.8%) | $1.63B(-4.3%) |
| Jun 2015 | - | $153.69M(-57.5%) | $1.70B(+2.1%) |
| Mar 2015 | $1.67B(+12.4%) | $361.45M(-26.7%) | $1.67B(-29.4%) |
| Dec 2014 | - | $493.12M(-29.2%) | $2.37B(+2.4%) |
| Sep 2014 | - | $696.63M(+491.2%) | $2.31B(-7.9%) |
| Jun 2014 | - | $117.83M(-88.9%) | $2.51B(+68.9%) |
| Mar 2014 | $1.48B(-63.1%) | $1.06B(+142.3%) | $1.48B(+247.7%) |
| Dec 2013 | - | $436.63M(-51.2%) | $427.06M(-4563.4%) |
| Sep 2013 | - | $895.35M(-198.9%) | -$9.57M(-98.9%) |
| Jun 2013 | - | -$904.92M(-170.9%) | -$904.92M(-123.8%) |
| Mar 2013 | $4.02B(-5.6%) | - | - |
| Mar 2012 | $4.26B(+12.3%) | - | - |
| Mar 2011 | $3.80B(-7.6%) | $1.28B(+62.0%) | $3.80B(+4.4%) |
| Dec 2010 | - | $787.48M(-39.9%) | $3.64B(-4.7%) |
| Sep 2010 | - | $1.31B(+210.2%) | $3.82B(+1.9%) |
| Jun 2010 | - | $422.68M(-62.1%) | $3.75B(-8.8%) |
| Mar 2010 | $4.11B(+25.2%) | $1.12B(+15.7%) | $4.11B(+37.3%) |
| Dec 2009 | - | $965.04M(-22.3%) | $2.99B(+47.6%) |
| Sep 2009 | - | $1.24B(+58.1%) | $2.03B(+158.1%) |
| Jun 2009 | - | $785.33M | $785.33M |
| Mar 2009 | $3.28B(+27.8%) | - | - |
| Mar 2008 | $2.57B(+43.4%) | - | - |
| Mar 2007 | $1.79B(-45.8%) | - | - |
| Mar 2006 | $3.30B(+20.0%) | - | - |
| Mar 2005 | $2.75B(-0.2%) | - | - |
| Mar 2004 | $2.76B(+27.5%) | - | - |
| Mar 2003 | $2.16B(+12.3%) | - | - |
| Mar 2002 | $1.93B(-0.0%) | - | - |
| Mar 2001 | $1.93B(+34.4%) | - | - |
| Mar 2000 | $1.43B | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual cash flow from operations?
- What is the all time high annual CFO for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual CFO year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly cash flow from operations?
- What is the all time high quarterly CFO for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly CFO year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM cash flow from operations?
- What is the all time high TTM CFO for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM CFO year-on-year change?
What is Takeda Pharmaceutical Company Limited annual cash flow from operations?
The current annual CFO of TAK is $6.94B
What is the all time high annual CFO for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual cash flow from operations is $10.00B
What is Takeda Pharmaceutical Company Limited annual CFO year-on-year change?
Over the past year, TAK annual cash flow from operations has changed by +$1.98B (+39.81%)
What is Takeda Pharmaceutical Company Limited quarterly cash flow from operations?
The current quarterly CFO of TAK is $1.47B
What is the all time high quarterly CFO for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly cash flow from operations is $3.70B
What is Takeda Pharmaceutical Company Limited quarterly CFO year-on-year change?
Over the past year, TAK quarterly cash flow from operations has changed by -$533.27M (-26.67%)
What is Takeda Pharmaceutical Company Limited TTM cash flow from operations?
The current TTM CFO of TAK is $6.94B
What is the all time high TTM CFO for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM cash flow from operations is $10.27B
What is Takeda Pharmaceutical Company Limited TTM CFO year-on-year change?
Over the past year, TAK TTM cash flow from operations has changed by +$1.98B (+39.81%)